RD19 (Published 2008) - Report on the Maximum Allowable Cost Generic Drug Reimbursement Methodology

Visit the LIS Learning Center to learn more about the features of the Reports to the General Assembly.

Reports to the General Assembly

Publication Guidelines

RD19 - Report on the Maximum Allowable Cost Generic Drug Reimbursement Methodology

Published: 2008
Author: Department of Medical Assistance Services
Enabling Authority: Appropriation Act - Item 302 Y.1. (Regular Session, 2007)

Report

Executive Summary:
Annual report on the generic drug savings through the use of maximum allowable cost (MAC) reimbursement rate for generic pharmaceuticals in the Medicaid pharmacy program.